US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
ME

MEDP

Stock Medpace Holdings Inc
$587.52

Nasdaq Global Select Market · Healthcare · US

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-07-31
🕌 Held by MNZL HTR non-permissible income <0.01%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
🟠 NOT YET
More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.
53
of 100
Setup confidence — system conviction, not win probabilityC
Trade plan CANDLE · SCALP
Entry
$602.52
Stop
$594.37
Target
$618.82
Risk : Reward 2.0R
Why this signal?
Structure1 of 5 timeframes bullish · 39.1% aligned
VWAPPrice holding above VWAP ($587.47)
VolumeRelative volume 3.5× the 20-day average
Momentum10-day rate of change -4.2%
Overall readNOT YET

Medpace Holdings Inc (MEDP) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-31). See the full ratio breakdown and business-activity screen below for the reasoning.

Market & analysts
Price target
$581.83
-1.0% · 12 analysts
Institutional own.
91.2%
of shares
Momentum (10d)
-4.2%
rate of change
SMC grade
C · 53
39.1% aligned
COMPLIANT
Sharia compliance
🕌 MNZL
Held by real halal ETF(s)
<0.01%
Non-permissible income — HTR, from filings (2026-06-30)
C · 53
SMC grade — 39.1% timeframe alignment
-4.2%
Rate of change (10d)
$581.83
Price target (-1.0%) · 12 analysts
91.2%
Institutional ownership

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for MEDP — this runs off the critical path so the page paints first. It will appear here on its own.

Tracked investors holding MEDP
InvestorFirmPositionWeightAs of
Ken Fisher Fisher Asset Management $69M 0.0% 2026-06-30
Ray Dalio Bridgewater Associates $8M 0.0% 2026-06-30
Azzad Asset Management Azzad Asset Management $0M 0.0% 2026-06-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

620.75563.92507.09450.25393.422025-09-122026-03-132026-09-11

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
567.95
S2
572.79
S1
577.98
PIVOT
582.82
R1
588.01
R2
592.85
R3
598.04

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
544.322 637.718
±7.9% from 591.02, made 2026-09-02 · resolves 2026-09-09
SELL
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 22368 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

SELL
19 indicators
OscillatorsSTRONG SELL
0 buy · 4 neutral · 3 sell
Moving averagesBUY
7 buy · 0 neutral · 5 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)48.90NEUTRAL
Stochastic %K (14)20.67NEUTRAL
CCI (20)-50.82NEUTRAL
Williams %R (14)-79.33NEUTRAL
MACD (12,26,9)-4.28SELL
ROC (10)-3.93SELL
Momentum (10)-24.05SELL
EMA (10)591.36SELL
SMA (10)590.34SELL
EMA (20)592.38SELL
SMA (20)598.79SELL
EMA (30)587.46BUY
SMA (30)595.05SELL
EMA (50)572.21BUY
SMA (50)578.32BUY
EMA (100)544.64BUY
SMA (100)514.61BUY
EMA (200)540.14BUY
SMA (200)520.70BUY

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About Medpace Holdings Inc

Healthcare · Diagnostics & Research

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

medpace.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-07-23

CANDLE
Type · SCALP
602.52
Entry
594.37
Stop
618.82
Target
WIN
Outcome
Verdict

🟠 NOT YET

More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.

Scores: 1 bullish / 2 bearish

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

TimeframeBiasBars
📅 Daily RANGING 62
⏰ 4H BEARISH 36
🕐 1H BULLISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

2.17
MACD (no fresh cross)

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-08 · Asset managers net 912361 (-21819)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.